Bausch Health Companies, Inc. (BHC)
|Net Income (ttm)||-1.29B|
|Day's Range||28.42 - 28.81|
|52-Week Range||16.08 - 34.80|
|Price Target||42.68 (+49.0%)|
|Est. Earnings Date||Nov 2, 2021|
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded an... [Read more...]
In 2020, BHC's revenue was $8.03 billion, a decrease of -6.67% compared to the previous year's $8.60 billion. Losses were -$560.00 million, -68.68% less than in 2019.Financial Statements
According to 19 analysts, the average rating for BHC stock is "Buy." The 12-month stock price forecast is 42.68, which is an increase of 48.97% from the latest price.
LAVAL, QC, Oct. 21, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that Tom Vadaketh will join the Company as Chief Financial Office...
Eight Poster Presentations Include New Analyses of ARAZLO®, DUOBRII® and SILIQ® LAVAL, QC, Oct. 19, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Orth...
Bausch + Lomb: Positive Outcomes for Premium LuxSmart™ Intraocular Lenses, Following One-Year Real-World Experience
MONTPELLIER, France--(BUSINESS WIRE)--Bausch + Lomb today announced positive outcomes following the one-year real-world evaluation of its premium LuxSmart™ lens, since its European launch.
LAVAL, QC, Oct. 6, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its third-quarter 2021 financial results on Tuesday, Nov. 2, 2021. Bausch Health will ...
Bausch Health (BHC) achieves study endpoints in the phase III study evaluating its investigational drug NOV03 in patients with DED associated with MGD.
Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial Of NOV03 (perfluorohe...
LAVAL, QC and HEIDELBERG, Germany, Sept. 30, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Novaliq GmbH (...
LAVAL, QC, Sept. 29, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today released its annual Environmental, Social and Governance (ESG) Report (pre...
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the ...
One analyst crunches the numbers to come up with a share price valuation well above current levels.
Bill Ackman (Trades, Portfolio) was one of Wall Street's rising stars after the financial crisis. He made a name for himself by making two significant bets the rest of the market seems to have overlooked.
Reuters reports that Bausch Health Companies Inc (NYSE: BHC) will pay $300 million to settle an antitrust lawsuit related to illegally maintaining a monopoly on diabetes drug Glumetza. The FDA first app...
Bausch (BHC) reported earnings 30 days ago. What's next for the stock?
Data to Feature New Health Economic Outcomes Research of Treatment of Emergency Department Patients with Opioid-Induced Constipation LAVAL, QC, Sept. 2, 2021 /PRNewswire/ -- Bausch Health Companies Inc....
LAVAL, QC, Sept. 1, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that the Company will participate in multiple upcoming investor c...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch Health Companies Inc. - BHC
New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Bausch Health Companies Inc. ("Bausch or the "Company") (NYSE: BHC). Such investo...
The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 20...
Bausch (BHC) beats on earnings but misses on sales in the second quarter. The company also lowers its annual revenue guidance.
The turnaround isn't happening as fast as investors expected.
Bausch (BHC) delivered earnings and revenue surprises of 1.03% and -0.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Bausch Health Companies Inc (NYSE: BHC) has reported Q2 revenues of $2.1 billion, +26% Y/Y, and missing the consensus of $2.12 billion. Revenue increased organically by $380 million, or 23% Y/Y.
LAVAL, Quebec, Aug. 3, 2021 /PRNewswire/ -- Second-Quarter 2021 Financial Results Revenues of $2.100 Billion GAAP Net Loss of $595 Million Adjusted EBITDA (non-GAAP) 1 of $826 Million GAAP Cash Generat...
IPO Would Unlock Value in a Medical Aesthetics Leader Transaction Will Enable Bausch Health to Continue to Execute on its Previously Announced Spinoff of its Bausch + Lomb Eye Health Business LAVAL, QC,...